{
    "nctId": "NCT00931450",
    "briefTitle": "Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer",
    "officialTitle": "Pilot / Phase II Randomised, Double Blind, Placebo Controlled Multicenter Study With Biomarker Evaluation of Neoadjuvant Exemestane in Combination With Sunitinib in Post-menopausal Women With Hormone- Sensitive, Her-2 Negative Primary Breast Cancer.",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 70,
    "primaryOutcomeMeasure": "Recommended dose of sunitinib malate that can be combined with exemestane",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast carcinoma meeting the following criteria:\n\n  * Estrogen receptor-positive \u2265 50% or Allred score \\> 6\n  * HER-2 negative defined as IHC \\< 2+ and negative FISH/CISH\n  * Primary tumor measuring \u2265 3 cm if there is no node involvement\n  * Any T if N1 or N2 disease\n\n    * No inflammatory breast cancer (T4d)\n  * No metastatic disease\n* Measurable disease by mammography and/or ultrasound and MRI (if available)\n\nPATIENT CHARACTERISTICS:\n\n* Postmenopausal\n\n  * Prior bilateral oophorectomy\n  * \u2265 60 years of age\n  * \\< 60 years of age AND have experienced amenorrhea for \u2265 12 months in the absence of chemotherapy, tamoxifen, or toremifene OR have undergone ovarian suppression and follicle-stimulating hormone and estradiol levels in the postmenopausal range\n* ECOG performance status 0-1\n* ANC \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 10 g/dL\n* Serum creatinine \u2264 1.5 mg/dL OR creatinine clearance \u2265 50 mL/min\n* Bilirubin normal\n* AST and ALT \u2264 2.5 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 2.5 times ULN\n* Albumin \\> 2.5. g/dL\n* No known HIV infection\n* Adequate left ventricular ejection fraction (LVEF) at baseline defined as LVEF not below normal range by echocardiogram or MUGA\n* No evidence of prior uncontrolled hypertension\n\n  * Patients with controlled hypertension (systolic \\< 150 mm Hg and/or diastolic \\< 90 mm Hg) by antihypertensive therapies allowed\n* No prior uncontrolled or symptomatic angina, myocardial infarction, congestive heart failure, clinically significant arrhythmias, or prolongation of the QTc interval\n* No hemorrhagic or thrombotic events, including transient ischemic attack, pulmonary embolism, or deep-vein thrombosis, within the past 12 months\n* No gross hemorrhage within the past 6 months (e.g., gastrointestinal bleeding, hemoptysis, or hematuria)\n* No history or evidence of an inherited bleeding diathesis or coagulopathy at risk of bleeding\n* None of the following:\n\n  * Unable to swallow oral medications\n  * Active inflammatory bowel disease\n  * Partial or complete bowel obstruction\n  * Chronic diarrhea\n* No history of another malignancy within the past 5 years except for cured non-melanoma skin cancer or successfully treated carcinoma in situ of the cervix\n* No psychiatric disease or social situations that would limit compliance with study requirements or patient unwilling or unable to comply with protocol for the duration of study\n* No unstable or severe intercurrent medical condition that, in the opinion of the investigator, might interfere with the achievement of study objectives\n* No known immediate or delayed hypersensitive reaction or idiosyncrasy to drugs chemically related to exemestane or sunitinib malate or their excipients\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior or other concurrent chemotherapy, radiotherapy, immunotherapy, biologic therapy, or hormonal therapy for primary invasive breast cancer\n* No concurrent anticoagulant therapy except for low-dose anticoagulants (i.e., low molecular weight heparin or aspirin) for the prevention of deep-vein thrombosis\n* No chronic therapy with corticosteroids, except for steroids administered by inhalation\n* More than 4 weeks since prior major surgery and \u2265 7 days since prior minor surgery\n* No prior or other concurrent investigational anticancer agent\n* No concurrent participation in another clinical trial\n* No concurrent drugs with potential proarrhythmic activity\n* No concurrent known CYP3A4 inhibitors (i.e., grapefruit, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, clarithromycin, diltiazem, nefazodone, voriconazole, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, delavirdine)\n* No concurrent known CYP3A4 or CYP1A2 inducers (i.e., carbamazepine, dexamethasone, felbamate, omeprazole, efavirenz, tipranavir, phenobarbital, phenytoin, primidone, rifabutin, rifampicin, St. John's wort)",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}